Logo Image
News|Articles|October 2, 2023

FDA Approves Enable Injections’ Wearable Injector

The injector is designed for at-home or in-clinic use.

Enable Injections’ announced that FDA has approved its wearable injector.

The Empaveli Injector is a wearable device designed for adults suffering from paroxysmal nocturnal hemoglobinuria. It allows for hands-free drug delivery of up to 25 mL and can be used for at-home or in-clinic use.

In a press release, Enable Injections’ CEO Michael Hooven said, “The approval of the EMPAVELI Injector will enhance the patient experience of administering a large volume (20 mL) of subcutaneous therapy. Enable's purpose is to redefine drug delivery for the benefit of patients.

He continued, “We are excited about achieving this milestone and are looking forward to growing enFuse® partnerships to improve the patient experience around the world."

Source

(Oct. 2, 2023); Enable Injections, Inc.; Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval; https://www.prnewswire.com/news-releases/enable-injections-receives-first-us-food-and-drug-administration-fda-approval-301943542.html

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more